According to the NCI website, ripretinib is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)
Indikationen/Anwendungsmöglichkeiten gemäss NCI Website:
- Gastrointestinal stromal tumor that is advanced. It is used in adults whose cancer has been treated with at least three kinase inhibitors, including imatinib mesylate.
- Ripretinib is also being studied in the treatment of other types of cancer.
More Information in English: